Toggle navigation
Menu
Home
News
Local
National
World
Politics
Sports
Entertainment
Business
Health
News Tip Hotline
Weather
Bend
Traffic
Live Traffic Cams
Central Oregon
Mountain Passes
Road Reports
Trip Check
Gas Prices
Closures and Delays
Stations
KQAK-FM 105.7
The Peak 104.1
The Ranch 95.7 FM
KBNW-AM/FM
KRCO-AM
Events
Upcoming
Concerts
Submit An Event
Submit A PSA
Interviews
Inside Central Oregon
Central Oregon Spotlight
Water Wise Tips
HBG Interviews
Ray’s Random Questions
Just Used Cars as Heard on KQAK & The Ranch
About MCO
Contact/About Us
Advertise
Careers
Media Kit
Radio Stations
Contest Rules
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Industrial Estimate
Composite Estimate
500 Stocks Estimate
Gold
Crude Oil
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Pyxis Oncology
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Today 7:00 EDT
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
September 30, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Proposed Public Offering
September 29, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 09, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
September 08, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
September 08, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Upcoming Investor Conferences
September 01, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
August 13, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
June 30, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
May 14, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Upcoming Investor Conferences
May 13, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer
May 07, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results
March 23, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Interim CEO Appointment and Leadership Transition to Support Strategic Focus and Program Continuity
February 03, 2026
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
December 18, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Upcoming Investor Conferences
November 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Provides Business Update and Reports Third Quarter 2025 Financial Results
November 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present Translational Data and Key Biology Findings Elucidating the Mechanism of Action of MICVO at Upcoming Medical Meetings
October 13, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Appoints Alex Kane as Senior Vice President, Investor Relations & Capital Markets
October 09, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 30, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in September Investor and Industry Conferences
August 21, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update
August 14, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 30, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
May 15, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
May 14, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
April 25, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
April 02, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
March 25, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 18, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
March 03, 2025
From
Pyxis Oncology
Via
GlobeNewswire
Tickers
PYXS
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
581446795
Mozilla/5.0 (Windows NT 10.0; Win64; x64) AppleWebKit/537.36 (KHTML, like Gecko) Chrome/60.0.3112.113 Safari/537.36
00fbf3724072e3a4c643b60a8db5a8756c4f8c05
1
